An increased tissue expression of NSE and increased serum levels of NSE are associated with malignant tissue proliferation [18], and are elevated in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) [19]. Here, ENO2 is linked to digestive system neuroendocrine tumor, grade 1/2.